Skip to main content

PE-22-28 vs CJC-1295

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

PE-22-28

PE-22-28 is a synthetic peptide fragment derived from research on the SAMP8 mouse model of accelerated aging. It has shown potential for enhancing memory and reducing cognitive decline.

Full details →

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.

Full details →

Side-by-Side Comparison

AspectPE-22-28CJC-1295
MechanismDerived from the protein that is deficient in SAMP8 mice. May work by inhibiting protein phosphatase 2A methylesterase, thereby affecting memory-related signaling pathways.CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly.
Typical DosageResearch protocols vary. Intranasal dosing has been studied at various concentrations. Optimal human dosing not established.CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily.
AdministrationIntranasal administration preferred for CNS delivery. Research compound with limited human use data.Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted.
Side EffectsVery limited human data. Primarily studied in animal models for safety and efficacy.Water retention, tingling in extremities, potential increase in cortisol and prolactin levels.
Best For

Key Differences

Detailed Analysis

CJC-1295 and PE-22-28 are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose CJC-1295 for Muscle Growth, Fat Loss, Sleep Quality. Choose PE-22-28 for Cognitive Performance, Anti-Aging & Longevity.

Ready to Learn More?